JOINN Laboratories Overhauls Governance Rules and Adds Non-Executive Director

JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) just unveiled an update.

JOINN Laboratories (China) Co., Ltd. has announced a package of corporate governance changes, including proposed amendments to its Articles of Association and the rules of procedures for shareholders’ general meetings, as well as the nomination of Zhou Fengyuan as a non-executive director. The revisions are designed to align the company’s governance with the amended PRC Company Law, recent State Council decisions and China Securities Regulatory Commission rules on overseas listings, notably adjusting the board size, removing class shareholder provisions and updating its constitutional documents to reflect the latest regulatory environment, which may streamline decision-making and clarify shareholder structures for investors.

The most recent analyst rating on (HK:6127) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.

More about JOINN Laboratories (China) Co., Ltd. Class H

JOINN Laboratories (China) Co., Ltd. is a China-based company listed in Hong Kong, operating in the biomedical and pharmaceutical services sector. The company focuses on laboratory and research services that support drug development and related life sciences activities, serving both domestic and overseas capital markets under evolving PRC regulatory frameworks.

Average Trading Volume: 3,815,454

Technical Sentiment Signal: Hold

Current Market Cap: HK$23.84B

See more data about 6127 stock on TipRanks’ Stock Analysis page.